Document Detail

Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.
MedLine Citation:
PMID:  22697079     Owner:  NLM     Status:  In-Data-Review    
Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently not well controlled, despite intensive guideline-based therapy. The unique monoclonal antibody approved for patients with severe allergic asthma is omalizumab: a recombinant humanised murine against IgE antibodies. The aim of the present study is to investigate the effect of long-term anti-IgE on the thickening of the reticular basement membrane (RBM) and eosinophil infiltration in bronchial biopsies from patients with severe persistent allergic asthma. Biopsies were obtained from 11 patients with severe persistent allergic asthma before and after (12 months) treatment with omalizumab. RBM thickness and eosinophils were measured by using light microscope image analysis. A significant mean reduction in RBM thickness and eosinophil infiltration were measured after one-year omalizumab treatment. No correlation between eosinophil reduction and RBM thickness reduction was found. No correlation between each of the previous two parameters and clinical parameters was detected. In conclusion, our study showed that a substantial proportion of severe asthmatics reduced the original bronchial RBM thickness and eosinophil infiltration after one-year treatment with anti-IgE, thus emphasizing the possible role of omalizumab in affecting airway remodeling in severe persistent allergic asthma.
A M Riccio; R W Dal Negro; C Micheletto; L De Ferrari; C Folli; A Chiappori; G W Canonica
Related Documents :
2267279 - Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor...
1829489 - Systemic effects of collagen-impregnated aortoiliac dacron vascular prostheses on plate...
10555699 - Manifestations of factor viii inhibitor in the head and neck.
21178849 - Progression of cervical instabilities in rheumatoid arthritis (ra) -a prospective cohor...
17941829 - Immune tolerance therapy utilizing factor viii/von willebrand factor concentrate in hae...
9374919 - The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematologic...
10482479 - Epidemiological features and visual prognosis of behçet's disease.
2471249 - Interleukin-6 (il-6) and acute phase proteins in the disease course of patients with sy...
11700779 - Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic strok...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of immunopathology and pharmacology     Volume:  25     ISSN:  0394-6320     ISO Abbreviation:  Int J Immunopathol Pharmacol     Publication Date:    2012 Apr-Jun
Date Detail:
Created Date:  2012-06-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8911335     Medline TA:  Int J Immunopathol Pharmacol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  475-84     Citation Subset:  IM    
Allergy and Respiratory Diseases, DIMI, University of Genoa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  MicroRNA 143-145 deficiency impairs vascular function.
Next Document:  Effectiveness of nebulized hypertonic saline and epinephrine in hospitalized infants with bronchioli...